Zolgensma Loses Orphan Benefit in Germany After 'Very High Sales'

Novartis Calls For Change In How Germany Assesses Orphan Benefit

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".